Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
83,427 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Aug 2, 2026 | Blue Cross NC | Testing for Developmental Delay AHS - M2176PayerPolicy · BCBSNC-TESTING-FOR-DEVELOPMENTAL-DELAY-AHS-M2176-F73296A736 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Testing for Colorectal Cancer Management AHS - M2026PayerPolicy · BCBSNC-TESTING-FOR-COLORECTAL-CANCER-MANAGEMENT-AHS-M2026-507ABFB4CE | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Testing for Alpha-1 Antitrypsin Deficiency AHS - M2068PayerPolicy · BCBSNC-TESTING-FOR-ALPHA-1-ANTITRYPSIN-DEFICIENCY-AHS-M2068-CA1B302F7D | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Testing for 5-Fluorouracil Use in Cancer Patients AHS - M2067PayerPolicy · BCBSNC-TESTING-FOR-5-FLUOROURACIL-USE-IN-CANCER-PATIENTS-AHS-M2067-4148158AD5 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Serum Tumor Markers for Malignancies AHS - G2124PayerPolicy · BCBSNC-SERUM-TUMOR-MARKERS-FOR-MALIGNANCIES-AHS-G2124-6B3D5057CA | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease AHS - G2110PayerPolicy · BCBSNC-SERUM-TESTING-FOR-HEPATIC-FIBROSIS-IN-THE-EVALUATION-AND-MON-1557B7F2F8 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Serum Testing for Evidence of Mild Traumatic Brain Injury AHS - G2151PayerPolicy · BCBSNC-SERUM-TESTING-FOR-EVIDENCE-OF-MILD-TRAUMATIC-BRAIN-INJURY-AH-5712F1B62D | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Salivary Hormone Testing AHS - G2120PayerPolicy · BCBSNC-SALIVARY-HORMONE-TESTING-AHS-G2120-8861F62A38 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Red Blood Cell Molecular Testing AHS - M2170PayerPolicy · BCBSNC-RED-BLOOD-CELL-MOLECULAR-TESTING-AHS-M2170-22CF1262F2 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Proteogenomic Testing of Individuals with Cancer AHS - M2168PayerPolicy · BCBSNC-PROTEOGENOMIC-TESTING-OF-INDIVIDUALS-WITH-CANCER-AHS-M2168-B7DE6D2876 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Prostate Specific Antigen (PSA) Testing AHS - G2008PayerPolicy · BCBSNC-PROSTATE-SPECIFIC-ANTIGEN-PSA-TESTING-AHS-G2008-60A4590AF3 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Prostate Biopsy Specimen Analysis AHS – G2007PayerPolicy · BCBSNC-PROSTATE-BIOPSY-SPECIMEN-ANALYSIS-AHS-G2007-76DBBFABD7 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Prescription Medication and Illicit Drug Testing in the Outpatient Setting AHS - T2015PayerPolicy · BCBSNC-PRESCRIPTION-MEDICATION-AND-ILLICIT-DRUG-TESTING-IN-THE-OUTP-08C1C390BA | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Prenatal Testing for Fetal Aneuploidy AHS - G2055PayerPolicy · BCBSNC-PRENATAL-TESTING-FOR-FETAL-ANEUPLOIDY-AHS-G2055-AAC3493F86 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Prenatal Screening (Nongenetic) AHS - G2035PayerPolicy · BCBSNC-PRENATAL-SCREENING-NONGENETIC-AHS-G2035-EB0D72E3F1 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Prenatal Screening (Genetic) AHS - M2179PayerPolicy · BCBSNC-PRENATAL-SCREENING-GENETIC-AHS-M2179-BCBFA94F8A | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Pre-Implantation Genetic Testing AHS - M2039PayerPolicy · BCBSNC-PRE-IMPLANTATION-GENETIC-TESTING-AHS-M2039-E822F9B38B | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Pharmacogenetics Testing AHS - M2021PayerPolicy · BCBSNC-PHARMACOGENETICS-TESTING-AHS-M2021-DBF1503B99 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Pathogen Panel Testing AHS – G2149PayerPolicy · BCBSNC-PATHOGEN-PANEL-TESTING-AHS-G2149-8311C56727 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Parathyroid Hormone, Phosphorus, Calcium, and Magnesium Testing AHS - G2164PayerPolicy · BCBSNC-PARATHYROID-HORMONE-PHOSPHORUS-CALCIUM-AND-MAGNESIUM-TESTING-DA4F88437A | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Pancreatic Enzyme Testing for Acute Pancreatitis AHS – G2153PayerPolicy · BCBSNC-PANCREATIC-ENZYME-TESTING-FOR-ACUTE-PANCREATITIS-AHS-G2153-28CABF783C | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Pancreatic Cancer Risk Testing Using Pancreatic Cyst Fluid AHS - M2114PayerPolicy · BCBSNC-PANCREATIC-CANCER-RISK-TESTING-USING-PANCREATIC-CYST-FLUID-A-6C75DC8E12 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Oral Cancer Screening and Testing AHS - G2113PayerPolicy · BCBSNC-ORAL-CANCER-SCREENING-AND-TESTING-AHS-G2113-8783F2B241 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Onychomycosis Testing AHS - M2172PayerPolicy · BCBSNC-ONYCHOMYCOSIS-TESTING-AHS-M2172-81B4DEB3A2 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Nerve Fiber Density Testing AHS - M2112PayerPolicy · BCBSNC-NERVE-FIBER-DENSITY-TESTING-AHS-M2112-AF02E62F6A | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Mutation Analysis in Myeloproliferative Neoplasms AHS - M2101PayerPolicy · BCBSNC-MUTATION-ANALYSIS-IN-MYELOPROLIFERATIVE-NEOPLASMS-AHS-M2101-396F2E375F | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Molecular Testing for Pulmonary Disease AHS - M2160PayerPolicy · BCBSNC-MOLECULAR-TESTING-FOR-PULMONARY-DISEASE-AHS-M2160-EFD87C7398 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Molecular Testing for Cutaneous Melanoma AHS - M2029PayerPolicy · BCBSNC-MOLECULAR-TESTING-FOR-CUTANEOUS-MELANOMA-AHS-M2029-8A7CCA1A43 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Molecular Profiling for Cancers of Unknown Primary Origin AHS- M2065PayerPolicy · BCBSNC-MOLECULAR-PROFILING-FOR-CANCERS-OF-UNKNOWN-PRIMARY-ORIGIN-AH-7E6CDB47AC | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Molecular Markers in Fine Needle Aspirates of the Thyroid AHS - M2108PayerPolicy · BCBSNC-MOLECULAR-MARKERS-IN-FINE-NEEDLE-ASPIRATES-OF-THE-THYROID-AH-514E691B9E | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Molecular Diagnostics for Breast Cancer Prognosis AHS - M2020PayerPolicy · BCBSNC-MOLECULAR-DIAGNOSTICS-FOR-BREAST-CANCER-PROGNOSIS-AHS-M2020-9B59A06ECC | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Molecular Analysis for Gliomas AHS - M2139PayerPolicy · BCBSNC-MOLECULAR-ANALYSIS-FOR-GLIOMAS-AHS-M2139-32C5F4F65A | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Minimal Residual Disease (MRD) AHS - M2175PayerPolicy · BCBSNC-MINIMAL-RESIDUAL-DISEASE-MRD-AHS-M2175-6BD507A6C0 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Microsatellite Instability and Tumor Mutational Burden Testing AHS - M2178PayerPolicy · BCBSNC-MICROSATELLITE-INSTABILITY-AND-TUMOR-MUTATIONAL-BURDEN-TESTI-4FFF3B76D7 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Metabolite Markers of Thiopurines AHS – G2115PayerPolicy · BCBSNC-METABOLITE-MARKERS-OF-THIOPURINES-AHS-G2115-5A2652DC15 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Lynch Syndrome AHS - M2004PayerPolicy · BCBSNC-LYNCH-SYNDROME-AHS-M2004-FEA8D2D8AA | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Lyme Disease Testing AHS – G2143PayerPolicy · BCBSNC-LYME-DISEASE-TESTING-AHS-G2143-B8298935F9 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Liquid Biopsy AHS - G2054PayerPolicy · BCBSNC-LIQUID-BIOPSY-AHS-G2054-95E2C8CF48 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Laboratory Testing for the Diagnosis of Inflammatory Bowel Disease AHS – G2121PayerPolicy · BCBSNC-LABORATORY-TESTING-FOR-THE-DIAGNOSIS-OF-INFLAMMATORY-BOWEL-D-A475F451B0 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Laboratory Procedures Medical Policy AHS - R2162PayerPolicy · BCBSNC-LABORATORY-PROCEDURES-MEDICAL-POLICY-AHS-R2162-5DEA6E0CDF | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Intracellular Micronutrient Analysis AHS – G2099PayerPolicy · BCBSNC-INTRACELLULAR-MICRONUTRIENT-ANALYSIS-AHS-G2099-45E8E56BD9 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | In Vitro Chemoresistance and Chemosensitivity Assays AHS- G2100PayerPolicy · BCBSNC-IN-VITRO-CHEMORESISTANCE-AND-CHEMOSENSITIVITY-ASSAYS-AHS-G21-964339457F | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Immunopharmacologic Monitoring of Therapeutic Serum Antibodies AHS - G2105PayerPolicy · BCBSNC-IMMUNOPHARMACOLOGIC-MONITORING-OF-THERAPEUTIC-SERUM-ANTIBODI-C5079D5972 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Immunohistochemistry AHS – P2018PayerPolicy · BCBSNC-IMMUNOHISTOCHEMISTRY-AHS-P2018-B9B4BA8C06 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Immune Cell Function Assay AHS - G2098PayerPolicy · BCBSNC-IMMUNE-CELL-FUNCTION-ASSAY-AHS-G2098-192947AB4C | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Identification of Microorganisms using Nucleic Acid Probes AHS – M2097PayerPolicy · BCBSNC-IDENTIFICATION-OF-MICROORGANISMS-USING-NUCLEIC-ACID-PROBES-A-9D1D6D0A3F | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Human Immunodeficiency Virus AHS – M2116PayerPolicy · BCBSNC-HUMAN-IMMUNODEFICIENCY-VIRUS-AHS-M2116-CBE84544E1 | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Hepatitis Testing AHS – G2036PayerPolicy · BCBSNC-HEPATITIS-TESTING-AHS-G2036-E4C8835DCB | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Helicobacter Pylori Testing AHS – G2044PayerPolicy · BCBSNC-HELICOBACTER-PYLORI-TESTING-AHS-G2044-905FC37B4E | New policy |
|---|
| Aug 2, 2026 | Blue Cross NC | Genomic Testing for Hematopoietic Neoplasms AHS- M2182PayerPolicy · BCBSNC-GENOMIC-TESTING-FOR-HEMATOPOIETIC-NEOPLASMS-AHS-M2182-4645B63D28 | New policy |
|---|